Literature DB >> 23385267

FDA regulation of off-label drug promotion under attack.

Aaron S Kesselheim1, Michelle M Mello, Jerry Avorn.   

Abstract

Mesh:

Year:  2013        PMID: 23385267     DOI: 10.1001/jama.2012.207972

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  Outcomes of off-label drug uses in hospitals: a multicentric prospective study.

Authors:  I Danés; A Agustí; A Vallano; C Alerany; J Martínez; J A Bosch; A Ferrer; L Gratacós; A Pérez; M Olmo; S M Cano Marron; A Valderrama; X Bonafont
Journal:  Eur J Clin Pharmacol       Date:  2014-09-09       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.